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ABSTRACT: What makes a high-quality biomarker experiment? The success of personalized medicine hinges on the an-
swer to this question. In this paper, I argue that judgment about the quality of biomarker experiments is me-
diated by the problem of theoretical underdetermination. That is, the network of biological and pathophysi-
ological theories motivating a biomarker experiment is sufficiently complicated that it often frustrates valid 
interpretation of the experimental results. Drawing on a case-study in biomarker diagnostic development from 
neurooncology, I argue that this problem of underdetermination can be overcome with greater coordination 
across the biomarker research trajectory. I then sketch an account for how coordination across a research tra-
jectory can be evaluated. I ultimate conclude that what makes a high-quality biomarker experiment must be 
judged by the epistemic contribution it makes to this coordinated research effort.
Keywords: biomarkers, personalized medicine, underdetermination, neurooncology.
RESUMEN: ¿Qué convierte a un experimento con biomarcadores en un experimento de gran calidad? El éxito de la me-
dicina personalizada depende de la respuesta a esta pregunta. En este artículo sostengo que el juicio sobre la ca-
lidad de los experimentos con biomarcadores está mediado por el problema de la subdeterminación teórica, es 
decir, la red de teorías biológicas y patofisiológicas que motivan un experimento con biomarcadores es lo bas-
tante complicada como para frustrar a menudo una interpretación válida de los resultados experimentales.  A 
partir de un caso de desarrollo de diagnóstico con biomarcadores, defiendo que el problema de la subdetermina-
ción puede ser superado con mayor coordinación en la trayectoria de investigación sobre el biomarcador. Des-
pués sugiero un enfoque para evaluar la coordinación a lo largo de una trayectoria de investigación. Por último 
concluyo que lo que hace que un experimento con biomarcadores tenga una alta calidad debe dirimirse en fun-
ción de la contribución epistémica que aquél realiza sobre este esfuerzo investigador coordinado. 
Palabras clave: biomarcadores, medicina individualizada, subdeterminación, neurooncología.
1. Introduction
What makes a high-quality biomarker experiment? The success of personalized medi-
cine hinges on the answer to this question. Since the ultimate goal of personalized med-
icine is to base treatment decisions on a patient’s biomarker status (e.g., the presence or 
absence of a genetic mutation), success requires that physicians have access to reliable 
*  This research received support under the PACEOMICS project, funded by Genome Ca nada, Genome 
Quebec, Genome Alberta, and the Canadian Institutes for Health Research (CIHR). I would like to 
thank Georgina Freeman, Jonathan Kimmelman, Brianna Barsanti-Innes, the audience at the PSX4 
Conference at the University of Pittsburgh, and the anonymous reviewers at this journal for helpful 
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biomarker diagnostics—i.e., biological assays that can accurately detect the biomarker 
and thereby predict whether or not a patient is likely to benefit from a course of treat-
ment. Indeed, a health-care system equipped with an array of valid biomarker diagnos-
tics could prevent much unnecessary patient suffering and health-care spending due to 
futile interventions.
Unfortunately, the quality of most biomarker experiments to date has been quite low 
(Kyzas et al. 2005, McShane et al. 2005, Mallett et al. 2009). This has lead to a “vicious cy-
cle,” where the evidence from biomarker experiments is poorly valued, biomarker research 
is poorly funded, and the costs of diagnostics are not reimbursed by health-care provid-
ers. Consequently, there is little incentive to improve the quality of evidence (Hayes et al. 
2013).
Although many commentators have discussed the technicalities of biomarker study de-
sign that contribute to these problems,1 some of the more fundamental philosophical issues 
remain unexplored. For example, in contrast to traditional clinical development, for which 
the unit of testing is a single agent (e.g., a drug), the relevant unit of testing in biomarker 
development is a more complex “intervention ensemble” (Hey and Kimmelman 2014). 
This ensemble combines (1) a diagnostic assay protocol, (2) a target biomarker, and (3) a 
particular course of therapy. Successfully translating this three-part “biomarker ensemble” 
into the clinic is a more challenging task than standard drug development, since it requires 
that researchers determine the optimal parameters and procedures for all of these compo-
nents.
In this paper, I will argue that this more complex ontology of testing gives rise to a 
particularly vexing problem of theoretical underdetermination. That is, the network of bi-
ological and pathophysiological theories motivating a biomarker experiment is often suffi-
ciently complicated and uncertain that it frustrates valid interpretation of the experimen-
tal results. To illustrate this problem, I begin in the next section by discussing a case-study 
in biomarker diagnostic development: The anti-cancer therapy, temozolomide (TMZ), 
has been extensively tested in patients with glioblastoma multiforme (GBM) whose tu-
mor specimens test positive for methylation of the O-6-methylguanine DNA methyl-
transferase (MGMT) promoter region of their DNA. But despite more than ten years 
of research, and seemingly wide agreement that a patient’s MGMT-methylation status 
can be predictive of their response to TMZ, MGMT diagnostic testing is not yet imple-
mented in the clinic.
In §3, I argue that the failure to fully translate MGMT testing into the clinical setting 
can be explained (at least in part) by underdetermination. Specifically, I show that many 
different theories are implicated in a biomarker experiment—these include the theory of 
how the drug interacts with the disease, the theory explaining the biomarker’s relationship 
to the drug and disease, and the theory explaining how the diagnostic assay(s) can reliably 
determine a patient’s biomarker status. In the case of MGMT testing for GBM response 
to TMZ, most of these theories are not yet well-confirmed (much less well-understood) 
and this uncertainty makes it difficult for researchers to judge the quality of emerging evi-
dence.
1  For example, the journal Clinical Trials (Oct. 2013) devoted an entire special issue to the technical 
challenges in designing and conducting biomarker studies.
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In §4, I argue that overcoming this difficulty requires greater coordination across the bi-
omarker research trajectory. Using the “Accumulating Evidence and Research Organization” 
(AERO) model—a graph-theoretic tool for representing and analyzing a scientific research 
program (Hey et al. 2013)—I then sketch an account of how coordination across a series of 
biomarker experiments could be evaluated. I ultimately conclude that the quality of a biomar-
ker experiment must be judged by the contribution it makes to a coordinated research effort.
2. The Case-Study: GBM, TMZ, and MGMT
GBM is a common and severe form of brain cancer. Most GBM patients will die within a 
year from the time of diagnosis. Prior to TMZ, the standard of care was surgical resection 
of the tumor (if feasible), radiotherapy, and treatment with a nitrosourea agent (e.g., car-
mustine, lomustine). Nitrosouras and TMZ are both alkylating agents, which inhibit the 
cancer cells’ repair activity by attaching an alkyl group to its DNA. However, TMZ is from 
the triazene class of drugs, and derived specifically from another widely-tested (although 
quite toxic) cancer drug, dacarbazine.
In 2005, TMZ received FDA approval as a first-line therapy against GBM. This de-
cision was largely based on the results of a single clinical trial conducted by the European 
Organization for Research and Treatment of Cancer (EORTC) (Stupp et al. 2005). The 
EORTC trial included 287 patients and compared TMZ plus radiotherapy treatment 
versus radiotherapy treatment alone. They observed an improvement in the median sur-
vival of patients by 2.5 months (14.6 month survival in the TMZ + radiotherapy arm ver-
sus 12.1 month survival in the radiotherapy-only arm). However, almost half (49%) of 
the patients in the TMZ arm experienced “one or more serious or life-threatening adverse 
events,” such as vomiting or convulsions (Pazdur 2013). Thus, at the time of TMZ’s FDA 
licensure, the best a GBM patient prescribed TMZ could hope for was about 2-3 more 
months of survival, albeit with relatively high risk of life-threatening side-effects. Unfor-
tunately, for the majority of GBM patients who still do not respond to TMZ therapy, they 
are just as likely to experience the serious side-effects without any survival benefit.
This is precisely the kind of situation that motivates research into personalized medi-
cines. Despite the fact that TMZ is an improvement on the previous standard of care, only 
some GBM patients respond to the chemotherapy. The hope for personalized medicine is 
that there is a testable biological property that distinguishes the responding from the non-
responding tumors. If this property can be prospectively identified, then it can improve the 
balance of risk and benefit for all patients: responders get effective treatment; non-respond-
ers are spared increased morbidity.
Fortunately, a subsequent retrospective analysis of the EORTC trial data by Hegi et al. 
(2005) revealed a biomarker—methylation of the MGMT promoter region—that seemed 
to identify a larger portion of the TMZ-responsive patients. MGMT is a gene that encodes 
for a DNA repair protein that fixes the damage caused by alkylating agents. In theory, if the 
promoter region of the MGMT gene is methylated, then this repair activity should be in-
hibited, and therefore, the patient should respond better to alkylating agents like TMZ (Es-
teller et al. 2000). Hegi et al. (2005) were able to show that for the patients given TMZ in 
the EORTC trial, the median survival for those with methylated MGMT was 21.7 months, 
versus 12.7 months for patients with unmethylated MGMT.
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This 9-month difference in median survival essentially launched the MGMT biomar-
ker research program. In the nine years since Hegi et al.’s study, the hypothesis that meth-
ylated MGMT should predict TMZ response has been tested in over three dozen stud-
ies. Yet, despite relatively wide agreement that MGMT’s status has the capacity to predict 
TMZ response, MGMT testing is still not recommended for general clinical use. For exam-
ple, the treatment guidelines of The National Comprehensive Cancer Network still only 
recommends MGMT diagnostic testing for very elderly (ages 70 and up) GBM patients 
(NCCN et al. 2012). The rationale is that these elderly patients are more likely to succumb 
to the toxicity of TMZ, whether they respond to therapy or not. And although this kind of 
stratification by age is certainly an advance in quality of care for the elderly subpopulation, 
it is still a long way from the more ambitious goal of personalized medicine—i.e., a predic-
tive MGMT diagnostic that can pick out all (or most) of the patient population who will 
benefit from TMZ.
3. Underdetermination and the Biomarker Ensemble
The contrast between the successful translation of TMZ as a stand-alone agent and its (as yet) 
unsuccessful translation as a personalized medicine is instructive for understanding the episte-
mological differences between traditional drug development and biomarker diagnostic devel-
opment. In traditional drug development, the unit of clinical translation is a single agent. Ac-
cordingly, we can think of the drug development program as largely driven by a single theory 
of disease and treatment mechanism, call it “TD”. In each clinical trial, there is a single hypoth-
esis, HD, about the effectiveness of the experimental treatment for a given patient population, 
P. If the new drug, “D” (developed on the basis of the theory TD), improves outcomes for pa-
tients in P, then this is taken to confirm both HD and TD. Whereas, if D fails to improve out-
comes, this is taken to disconfirm HD, and it may also signal a problem with the theory TD.
Yet, either outcome could also be erroneous—that is, an artifact of the experimental 
design or conduct, such as a protocol violation or a lack of control for bias. As many phi-
losophers of science and medicine have now recognized, clinical development is thus reg-
ularly encountering the problem of underdetermination (Anderson 2006, Howick 2009, 
Hey and Weijer 2013, Chin-Yee 2014, Hey 2015).2 The basic epistemic concern is that 
whether the experiment succeeds or fails—whether a clinical trial has a positive or nega-
tive result—there is always some uncertainty about the reliability of the result, the tested 
hypothesis, and the truth of the underlying theories motivating the experiment. Therefore, 
scientific judgment is needed to draw out the appropriate epistemic implications for TD 
and HD (Hey and Weijer 2013).
Now applying this formalization to the TMZ case, we can understand the aforemen-
tioned EORTC trial as a test of the hypothesis, HTMZ, that TMZ would be an effective 
2  I should acknowledge that there are a variety of formulations for the problem of underdetermination 
in the philosophical literature. It is also sometimes called “Duhem’s problem” or the “Duhem-Quine 
Problem” (Ariew 1984, Needham 2000, Darling 2002, Howson and Urbach 2006, Worrall 2010). 
Since a discussion of the relative philosophical merits of these accounts is outside the scope of this essay, 
I will just state that I am largely following the logical formalization of the problem implicit in Worrall 
(2010) and explicit in Hey (2014).
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treatment for adult GBM. Its positive result was taken by the FDA to confirm HTMZ suffi-
ciently for licensing the drug as a first-line treatment for the patient population, PGBM. This 
result could also be taken to have provided further confirmation of the theory, TAlk, which 
explains the general effectiveness of alkylating chemotherapies.
But as the problem of underdetermination teaches, the FDA’s decision to approve 
TMZ for this indication was not straightforwardly entailed by the evidence. The decision 
also reflects a judgment about the methodological quality of the EORTC study and the 
clinical value of a 2.5 month improvement in patient survival, despite an increase in toxic-
ity. Which is to say, the FDA could have ruled differently without any violation of reason. 
For example, they might have withheld approval on the grounds that the sample popula-
tion in the EORTC trial was not representative of the larger GBM population (i.e., calling 
into question the trial’s external validity). They could therefore have demanded another 
study be conducted with a different sample population. Or they might have argued that 
TMZ’s safety profile was too poor, and that even though the theory TAlk had been con-
firmed in the study, the relevant hypothesis, HTMZ, had not yet been sufficiently confirmed, 
since the balance of risk and benefit was not positive enough to conclude clinical effective-
ness, even if it had shown biological efficacy (Tunis et al. 2003).
However, I do not want to get bogged down here in contemplating counter-factual 
FDA judgments. The essential points is, first, to show how the problem of underdetermi-
nation can play out in the standard model of clinical translation; and second, to observe 
that this model of underdetermination does not accurately characterize biomarker devel-
opment. This is because the relevant unit of translation is not a drug or a diagnostic per se, 
but an “intervention ensemble,” which includes a sensitive and specific assay protocol, a rig-
orously defined biomarker-positive population, a particular drug dose and schedule, vari-
ous co-interventions, delivery techniques, and so on (Hey and Kimmelman 2014). Success-
ful biomarker translation requires that optimal (or clinically sufficient) values for each of 
these components have been determined.
To illustrate: Consider that Hegi et al.’s (2005) retrospective study used a methylation-
specific polymerase chain reaction (MS-PCR) assay to amplify the MGMT promoter re-
gion of the patient’s tumor specimen. The association they demonstrated between a meth-
ylated MGMT promoter and benefit from TMZ therefore depends on at least four other 
dimensions of epistemic uncertainty. These are:
1. The theory of the biomarker, call it “TMGMT,” explaining MGMT’s relationship to 
the drug and disease (i.e., reduced activity of the DNA repair enzyme that counter-
acts alkylation therapy should correlate with increased drug activity);
2. The biomarker hypothesis, HMGMT, that methylated MGMT will accurately dis-
tinguish the TMZ-responsive patients in the sample population, pGBM, from the 
non-responsive;
3. The theory of the diagnostic, call it “TPCR,” explaining the assay’s relationship to 
the marker, drug, and disease (i.e., that there exists an MS-PCR protocol that is 
sufficient to accurately detect the relevant region and extent of MGMT methyla-
tion in specimens drawn from PGBM);
4. The diagnostic hypothesis, HPCR, that patient specimens testing positive for 
MGMT methylation with a specific MS-PCR protocol can reliably distinguish 
TMZ-responsive patients in pGBM from the non-responsive.
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The epistemic status for all of these elements necessarily mediates the interpretation of the 
study results. For example: If we observe a positive association between biomarker-status 
and treatment response, is this due to a truly predictive biomarker (i.e., confirmation of 
TMGMT) or is it merely an artifact of the assay? Or if we observe a null result, does this in-
dicate a useless biomarker (i.e., disconfirmation of TMGMT) or might the biomarker still be 
predictive for a more narrowly defined patient population (i.e., disconfirmation of HMGMT, 
but not necessarily disconfirmation of TMGMT)?
What if one kind of assay confirms a biomarker’s utility and a second assay disconfirms 
it? If one assay is not already known to be more reliable than the other, then what does this 
discordance tell us about the relationship between the assays, the biomarker, and the treat-
ment? Or perhaps the observed association between biomarker and response may be con-
founded by another biomarker altogether?
All of these questions bear on the judgments of experimental quality and the interpre-
tation of evidence. Yet, insofar as any of the theories and hypotheses underlying the disease, 
drug, biomarker, or assay remain uncertain, it should accordingly reduce our confidence in 
providing definitive answers. Until researchers can assert with confidence that, for example, 
“this MS-PC assay protocol is 90% sensitive and specific for detecting methylated MGMT 
in the sample population, and testing positive confers ten-fold greater odds of responding 
to TMZ,” then the final goal of personalized medicine has not yet been achieved.
Moreover, we should observe that biomarker experiments cannot support valid infer-
ences independent of the basic scientific theories in the way that traditional, late-phase 
drug trials can. For example, Ashcroft (2004) argues that randomized controlled trials 
(RCTs) can provide valid answers to the clinical question of interest—i.e., “Should we pre-
scribe drug A or B for the population with the condition PC?”—without needing a true 
causal theory, TA or TB, for why the drugs are effective. Howick (2011) also makes a similar 
claim— arguing that the value of theoretical or mechanistic reasoning is overemphasized in 
medical research. In essence, these authors both suggest that the driving theories in an RCT 
may be entirely wrong and, at least in principle, it should make no difference at all to clini-
cal practice. All that matters is for the RCT to get it right about which intervention is bet-
ter (and that neither falls below the standard of competent medical care).3
However, biomarker development is not like this. To begin with, most biomarker ex-
periments are retrospective analyses of archived tissues and are not conducted in the con-
text of an RCT. Therefore, they are not directly addressing a pragmatic, clinical question 
about which biomarkers we should use in practice. But even more fundamentally, biomar-
ker development is explicitly trying to leverage the theories and techniques of basic science 
toward better treatment practices. Therefore, by definition, biomarker translation cannot 
be successful until it has resolved these theoretical uncertainties.
The development of another personalized medicine, the epidermal growth factor 
receptor (EGFR)-inhibitor, cetuximab, provides an illuminating example here: Cetuxi-
mab was initially approved by the FDA for use against metastatic colorectal cancer for 
patients whose tumors tested positive for elevated EGFR-protein expression. However, 
3  I should note that the alleged independence of theory from RCTs is a controversial position. For exam-
ple, Giacomini (2009), Hey (2014), and Kimmelman and London (2015) all argue that theories and 
theoretical understanding have an essential role to play in clinical development.
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it was later discovered that non-EGFR-expressing patients also responded, and in fact, it 
was a different genetic marker altogether—mutation of the KRAS gene—that predicted 
response to cetuximab (Chung et al. 2005). Although cetuximab is generally considered 
a success for personalized medicine, this initial misidentification of the biomarker en-
semble had serious repercussions for the quality of health care. Many patients who could 
have benefited from cetuximab (i.e., those with low EGFR-expression) were deprived of 
effective care; and patients who were not likely to respond (i.e., those with high EGFR-
expression but KRAS-mutations) were prescribed an expensive, highly-toxic, and ineffec-
tive treatment.
These unfortunate consequences can be attributed to an inadequate understanding and 
testing of the basic theories concerning cetuximab, EGFR-inhibition, and protein expres-
sion assays. Since cetuximab was explicitly developed as an EGFR-pathway inhibitor, it is 
certainly plausible to think it should work better for patients whose tumors showed elevated 
EGFR protein expression. However, researchers did not actually test this theory before the 
biomarker ensemble was approved. Indeed, the trials in support of cetuximab’s approval 
as a personalized medicine systematically excluded patients with low EGFR-expression 
(C unningham et al. 2004). This means that although researchers were able to show and ex-
plain improvements over the standard of care on the basis of a flawed theory, they left a criti-
cal dimension of uncertainty unresolved. In retrospect, it is clear that this lack of theoretical 
resolution resulted in worse patient outcomes and greater health-care inefficiencies—exactly 
the opposite of what personalized medicine is supposed to achieve.
In the case of TMZ and MGMT testing, at least some of these dimensions of theo-
retical uncertainty do seem to be resolved. The general characterization of the relevant bi-
omarker and patient population parameters are largely settled (MGMT and newly-diag-
nosed GBM, respectively). But uncertainty still remains about the optimal assay (Febbo 
et al. 2011, Wick et al. 2014). Most studies examining an MGMT biomarker for predict-
ing TMZ response have followed Hegi et al. (2005) in using MS-PCR. But some critics ar-
gue that this assay is unreliable when used with archived tissue samples (Dunn et al. 2009). 
Given that many MGMT biomarker studies are retrospective analyses of archived tissues 
(including Hegi et al.’s study), this criticism calls into question the quality of much of the 
available evidence.
One of the alternative assays to MS-PCR is immunohistochemistry (IHC). Rather 
than amplifying the promoter region of the DNA, IHC assays expression of the MGMT 
repair protein directly. Although IHC also appears to predict TMZ-responders (Chinot 
et al. 2007), studies that have directly compared IHC and MS-PCR have found that the 
methods are not interchangeable (Mellai et al. 2009, Lechapt-Zalcman et al. 2012). On its 
face, this discordance suggests problems with the underlying theories TMGMT, TPCR, and 
TIHC. Specifically, it challenges the assumed identity and mechanistic relationship between 
MGMT promoter methylation (as assayed by MS-PCR) and MGMT protein expression 
(as assayed by IHC). Researchers have generally assumed that both properties are causally 
connected to alkylation-damage repair, and should therefore predict response to TMZ, but 
this theoretical uncertainty has not been resolved.
To complicate matters further, Lechapt-Zalcman et al. (2012) found that although 
MS-PCR and IHC selected different biomarker-positive patient populations in their sam-
ple, the hazard ratio for death was nearly identical (0.46 for MS-PCR; 0.45 for IHC). From 
a health-care system perspective, this suggests that either assay may be suitable for clinical 
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use, since each selects a population that is more likely to benefit from TMZ therapy. How-
ever, from a patient perspective, discordance between the assays is a cause for concern. A 
patient classified as MGMT-negative on one test may be MGMT-positive on the other. 
Given that positivity on either test correlates to better outcomes, if treatment decisions are 
to be based on the test result, it would be in the patient’s best interest to demand both tests. 
But even then, the ever-present possibility of misclassification (that is, either a false-positive 
or false-negative result) might encourage patients to skip the added cost and burden of the 
diagnostics altogether and simply go ahead and prescribe TMZ.4
This lingering uncertainty about the theories underlying alternative MGMT assays, as 
well as the possibility of misclassification, helps to explain why MGMT testing is not yet 
implemented in the clinic. In essence, the unit of translation has not yet been determined. 
Or in other words: The outstanding question that needs to be answered in future biomar-
ker experiments is not simply if MGMT can be predictive of response to TMZ (since we 
already know that it can). Rather, the question now is: “What are the necessary and suffi-
cient conditions for leveraging a methylated-MGMT diagnostic in order to maximize the 
therapeutic benefit of first-line TMZ in adult GBM patients?” To adequately address this 
question—and avoid the kinds of mistakes made with cetuximab—researchers will need to 
resolve the many remaining dimensions of uncertainty concerning the assays (e.g., TPCR, 
TIHC, HPCR, HIHC,...).
4. Study Quality and the Division of Epistemic Labor
One obvious recommendation for resolving these uncertainties is to design and conduct 
more rigorous experiments. As I noted in the introduction, the majority of criticisms in the 
biomarker literature have focused on this aspect of the problem. For example, Simon et al. 
(2009) point out that many biomarker studies do not report how (or if) they blinded assay 
evaluators to the patient’s clinical status. Study reports also often fail to provide a prospec-
tive definition for the cut-off value used when judging biomarker-status and do not ade-
quately describe the use of control specimens.
For retrospective analyses, which typically rely on “convenience samples” of archived 
specimens from a local institutional biobank, Simon et al. also emphasize the danger of bi-
ased sampling. The worry is that there may be a causally relevant difference between ar-
chived specimens that give meaningful assay results from those deemed “inadequate” for 
testing. Thus, they argue that the sample patient population, from which all specimens 
will be drawn, must be prospectively defined with clear eligibility criteria. And then at least 
66% of the defined patient population must provide specimens that produce meaningful 
assay results.
It is also rare for biomarker studies to report estimates of the sensitivity and specificity 
for their assays. And yet, without this information, it is difficult to judge whether the assay 
used in a study has adequately demarcated the biomarker-positive and biomarker-negative 
populations. This uncertainty weakens any inferences about the biomarker’s clinical valid-
ity and utility (McShane and Polley 2013). As noted above, for studies that use multiple 
4  According to Wick et al. (2014), this is precisely what physicians and patients are currently doing.
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assays, disagreement in classification between the assays is potentially informative for un-
derstanding the posited theoretical relationships among the biomarker, the assays, and the 
disease. But of course, if misclassification rates are not reported, then the opportunity to re-
duce this uncertainty is lost.
Some of these technical problems could be straightforwardly addressed through bet-
ter reporting practices. Indeed, this is the goal of the REMARK guidelines, which provide 
a checklist of methodological items that every published biomarker experiment should re-
port (McShane et al. 2005). Although adherence to these guidelines has been poor (Mallett 
et al. 2009), better reporting would be a big first step toward improving the general quality 
of evidence in the biomarker research enterprise.
However, we should be careful not to conflate the value of better reporting with the 
demand for more rigorous biomarker study designs. High-quality reporting is a necessary 
condition for supporting sound judgments about the evidence in the published literature 
(Glasziou et al. 2014). We can therefore assert the need for better reporting without quali-
fication. In contrast, the call for more rigorous biomarker study designs needs to be care-
fully qualified. This is due to the division of epistemic labor in medical research between 
exploratory and confirmatory investigations (Kimmelman et al. 2014, Hey and Kimmel-
man 2014).
In the biomarker context, we can think of exploratory studies as hypothesis-generating 
and hypothesis-pruning. Their role is to expand or narrow the parameter space for a clini-
cally viable intervention ensemble. Whereas confirmatory studies are hypothesis-testing. 
Their role is to put a particular set of ensemble parameters to a decisive test. Accordingly, it 
would be overhasty to dismiss some of the less rigorous, more exploratory biomarker studies 
as uninformative or misleading. For example, rather than prospectively defining a biomarker 
cut-off, an exploratory study might only retrospectively compare the predictive utility for 
multiple biomarker cut-offs in their study population. Or it might compare multiple differ-
ent assays, and therefore, the rate of successful results (if agreement between assays is a pre-
specified requirement for success) may fall below the 66% threshold. Although these kinds 
of investigations should not be taken to provide definitive evidence for or against a biomar-
ker’s utility, they can still make a valuable epistemic contribution. But the precise value of 
this contribution will be relative to the accumulating state of scientific evidence. In the early 
stages of development, it should not be troubling to find less rigorous and more exploratory 
studies, since investigators may still be foraging for viable ensemble parameters. However, 
as more evidence accumulates about the range of viable biomarker ensemble parameters, we 
should expect that exploratory studies will give way to more confirmatory investigations.
This model for the division of epistemic labor also implies that it would be inefficient 
to demand that all biomarker studies have a rigorous, confirmatory orientation. As impor-
tant as confirmatory studies are for providing definitive answers, a premature confirma-
tory investigation—i.e., one conducted before researchers can be confident that they have 
adequately explored the parameter space—would only show that one particular set of en-
semble parameters is not useful. When the range of viable ensemble parameters is poorly 
understood, this is not particularly valuable information. Thus, the ideal is to use both ex-
ploratory and confirmatory orientations in a complimentary and coordinated research ef-
fort. Exploratory studies map the ensemble parameter space in search of the most prom-
ising biomarker ensemble. Confirmatory studies then take this ensemble and put it to a rig-
orous test.
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5. Robustness and Coordination of Research Activities
In a recent article, I argued that the entire process of clinical drug development can be 
thought of as a multi-modal robustness analysis (Hey 2015). In virtue of its translational 
trajectory through in vitro, in vivo, and human experiments, an approved drug is a robust 
intervention. Much the same can be said for biomarker diagnostic development, except, as 
we saw in §3, there are more parameters of uncertainty to resolve in translating a biomar-
ker ensemble. A truly successful biomarker diagnostic has been analytically validated, then 
shown to predict patient benefit in archived specimens, and finally, passed decisive evalua-
tion in clinical trials (Simon 2012). Indeed, success through this trajectory should be suffi-
cient to furnish physicians with a robust understanding about how to use and interpret the 
results of a diagnostic test.
How then might a series of biomarker experiments coordinate their activities toward 
this robust clinical understanding? As a first step, we can clarify some kinds and proper-
ties of a biomarker’s translational trajectories that we do not want. First, we do not want a 
“black box” translation—that is, a trajectory which identifies an effective biomarker ensem-
ble, but fails to either adequately explore the parameter space or illuminate anything about 
the underlying theories. Physicians will often need to make adjustments to an intervention 
ensemble in practice—e.g., reducing dose in the face of patient toxicity or deciding about 
treatment in cases of borderline diagnosis. If physicians do not have any empirical or theo-
retical basis for making these judgments, then the research system has failed to adequately 
inform clinical practice. And as the cetuximab case makes clear, having a “black box” per-
sonalized therapy can actually diminish the overall quality of health care.
Second, we should strive for efficiency of translation, avoiding unnecessary duplication 
of study questions. The pool of human and material resources for research is limited. Some 
replication or verification of study results is certainly desirable, but once a question has 
been answered, it is important for investigators to articulate novel—and still unsettled—
hypotheses. Yet, as noted above, efficiency must be balanced against the risk of a premature 
confirmatory investigation. A biomarker hypothesis that has only been tested in explora-
tory-type studies is not yet ready to be folded into a large RCT. Positive results should first 
be replicated and then refined through a systematic robustness analysis that identifies the 
set of assay, biomarker, therapy, and population parameters most likely to prove clinically 
useful (McShane and Polley 2013). Once this process is complete, and the biomarker en-
semble is sufficiently defined, only then is it truly ready for a decisive clinical evaluation in 
an RCT.
Third, we want to avoid unnecessary risk. This is related to the second concern, since 
the risks of study participation are not sufficiently redeemed in either a study that investi-
gates a settled research question or a study that inefficiently expends research resources on 
a premature confirmatory test. Safety information is also accumulating over the course of 
the research trajectory, and this information should be used to design safer human experi-
ments. Thus, prospective biomarker studies—particularly RCTs that allocate patient-sub-
jects on the basis of their biomarker status—that are not designed on the basis of the most 
recent available evidence may be exposing patients to unnecessary risks and burdens.
These three restrictions on the ideal biomarker translation are grounded in the prin-
ciples of research ethics—specifically, the principles of risk minimization, social value, 
and protecting the integrity of the research enterprise. These principles also imply two 
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other properties of the ideal translation that are worth making explicit: First, every study 
should be explicitly designed to incorporate and build upon the accumulating state of ev-
idence. This requirement not only helps to satisfy the concerns about unnecessary dupli-
cation and risk, it also facilitates a more efficient and robust research process. Second, the 
testing hypotheses should evolve over time. When a biomarker is first identified, it is com-
mon to see vague and qualitative hypotheses about its role in predicting treatment response 
(e.g., “MGMT repairs the damage caused by TMZ, therefore we investigated the impact 
of methylated MGMT on treatment response”). These kinds of qualitative claims are suf-
ficient early on in the research program, but as evidence accumulates, the biomarker hy-
potheses should become more precise and quantitative (e.g., “We expect patients that test 
positive for methylated-MGMT using MS-PCR to average 5-months longer survival”). 
Confirmation or refutation of these quantitative claims is needed to support the imple-
mentation of biomarker diagnostics in clinical practice. Physicians, in particular, need this 
information in order to effectively interpret the results of diagnostics for their patients. 
Therefore, it is incumbent on researchers to progressively refine the viable hypotheses.
Putting all of these principles together, we can articulate a heuristic research strategy 
for biomarker translation: Ideally, we should like to see early studies exploring a wide array 
of ensemble parameter values—that is, testing multiple biomarkers, comparing the accu-
racy of multiple assays, evaluating the biomarker’s utility for different patient populations, 
etc. Once some promising ensemble combinations have been identified, later studies sub-
mit these to a definitive test.
Yet it is one thing to articulate a coordinated research strategy, it is quite another to 
implement or evaluate it. Indeed, the need for greater coordination has been recognized 
across the clinical research enterprise—not just in the realm of biomarker development 
(Boucher et al. 2009, Seymour et al. 2010, Hayes et al. 2013, Hay et al. 2014). But, as Hey 
et al. (2013) observe, one of the barriers to improving coordination has been a lack of tools 
or frameworks for analyzing or communicating the state of coordination.
As a potential remedy to this problem, Hey et al. (2013) developed the “AERO 
model”—a graph-theoretic model for representing the accumulating state of evidence and 
organization of research activities within a given scientific domain. Briefly, this model visu-
ally represents a set of study reports (ideally drawn from a systematic literature review) as 
nodes in a directed network, arranged along the x-axis by time, and stratified on the y-axis 
by various study parameters. Arrows (or edges) between nodes are then used to indicate in-
ferential relationships between studies.
Table 1 lists 37 studies that investigated the utility of an MGMT assay for predicting 
TMZ response in adult GBM patients.5 In addition to basic study details—e.g., authors, 
year of publication, retrospective versus prospective design, type of assay, and significance 
of outcome—this table also includes a rough quality metric, or “Q-score”. This Q-score, 
based on the recommendations in Simon et al. (2009), is a 5-point scale, where 1 point each 
is awarded for reporting (1) blinded assessment; (2) prespecified definition for biomarker-
positive status; (3) use of control specimens; and (4) biomarker status successfully deter-
mined for greater than 66% of collected specimens.
5  This set of 37 studies is the result of a systematic review, whose technical details are described in Hey et 
al. (n.d.).
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Table 1.  Studies evaluating an MGMT assay for predicting first-line TMZ response 
in adult GBM. The “ID” column corresponds to the node in the AERO 
diagrams. “Q” is a 5-point quality score, where 1 point each is awarded for 
1 point each is awarded for reporting (1) blinded assessment; (2) prespecified 
definition for biomarker-positive status; (3) use of control specimens; 
and (4) biomarker status successfully determined for greater than 66% of 
collected specimens. “OS-18” is the significance of the association between 
MGMT-status and 18-month patient survival.
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Figure 1 illustrates the AERO model applied to these studies. Circular nodes in the fig-
ure represent prospective clinical trials that included a biomarker component (the larger 
node is a phase 3 trial, the others are phase 2), square nodes represent retrospective stud-
ies. Nodes are white if the authors showed a statistically significant association between 
MGMT status and survival at 18 months; nodes are shaded if the association was not sig-
nificant (i.e., null results).6 The nodes are stratified here by the type(s) of diagnostic assay 
used, either MS-PCR (the most common), direct comparison of “Multiple” assays, IHC, or 
pyrosequencing (PSQ).
Figure 1.  AERO graph for studies investigating MGMT testing as a predictive diagnostic 
for first-line TMZ therapy in adult GBM patients. Solid arrows are all 
references to Hegi et al. (2005)—the landmark retrospective study
The arrows between the nodes represent the most recent citation to other studies in the 
sample that appeared in either the introduction or methods section of the published re-
port. For example, the arrow between node 2 and node 6 indicates that study 2 was the 
6  What is a clinically relevant outcome varies among types of cancer. As described earlier, median survival 
for a GBM patient given TMZ (without the use of a biomarker diagnostic) is around 14.6 months. 
Therefore, 18-month survival represents a clinically significant improvement that could justify the use 
of a predictive diagnostic.
220 Spencer Phillips Hey
Theoria 30/2 (2015): 207-227
most recently cited study in the introduction and methods section of study 6. While this 
method for representing the flow of evidence is certainly an imperfect proxy measure for 
coordination of research activity, it is still informative. The introduction and methods are 
those sections of a scientific report responsible for articulating the rationale for the tested 
hypothesis. Authors that do not explicitly reference recent and available evidence as the 
justification for their hypothesis are arguably conducting inefficient and ethically question-
able research.
Figure 1 reveals a number of interesting properties of the TMZ-MGMT research pro-
gram: First, the majority of studies were positive—finding a significant association between 
methylated-MGMT and the odds of survival to 18 months. Yet, the proportion of positive-
to-null studies is not overwhelming. After 2011, this ratio actually shifts in favor of null re-
sults. Nevertheless, the only phase 3 trial in this sample did find a significantly positive associ-
ation (Gilbert et al. 2013). This is a promising sign for the clinical utility of MGMT testing.
Second, we can observe that after 2011, more studies are directly testing multiple as-
says. This indicates an evolution of the testing hypothesis. Specifically, it reflects a shift in 
focus from the question “Is MGMT a predictive marker?” to “What is the optimal assay 
for maximizing the clinical utility of an MGMT marker?” However, this shift in the test-
ing hypothesis also calls into question the epistemic value of some of the later studies that 
only looked at MS-PCR. Given the early positive results in this stratum, it is not surprising 
to see continued interest. And indeed, some this work is surely consistent with the need to 
validate early exploratory results. Nevertheless, by 2010 or 2011, when 10 or more studies 
have already retrospectively investigated this method, further investigations seem problem-
atic. Why has this question not been adequately answered? What more can these studies 
plausibly teach us about the predictive value of an MS-PCR diagnostic?
This leads to a third point: The continued references to Hegi et al. (2005) as justifi-
cation reflect a failure (on the part of some studies) to update their hypothesis in light of 
the accumulating state of evidence. 14 of the 30 total justifications are to this one study. 
While this is not troubling in the early years of the research program, as more studies are 
completed and published, it becomes ethically and scientifically problematic to ignore the 
growing body of evidence. This study’s modest Q-score also undermines the explanation 
that it is so heavily cited because of its methodological rigor.
Finally, the overall “shape” of the trajectory appears to be the reverse of our ideal. That 
is, the wide-exploration of assay parameters—evident in the cluster of studies in the “Mul-
tiple” stratum post-2011—takes place later in the research trajectory. These studies are 
doing essential epistemic work toward resolving the biomarker ensemble parameters. But 
ideally, this work would be immediately after the identification of a promising marker. In-
stead, what we see is a large portion of the research program that was content for some time 
to investigate and re-investigate the same set of ensemble parameters.
Figure 2 builds on these criticisms by applying two additional layers of analysis. Nodes 
are now shaded according to their Q-score, and edges styled according to the recency of 
the citation. For the latter, the rule was as follows: Cited justifications to evidence within 
the previous 3 years are solid edges; citations to evidence older than this are represented 
with dotted edges. Although 3 years may be an arbitrary cut-off, for retrospective studies—
which are often studies of convenience and can be completed much more quickly than a 
prospective trial—this should still be more than enough time to expect that authors have 
read and folded the more recent and relevant literature into their design.
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This alternative coding scheme makes the contrast in epistemic value even clearer: 
Post-2011, experiments in the MS-PCR only stratum were generally of lower quality and 
tended to ignore the accumulating body of evidence. Only 1 of the 8 studies in this region 
of the graph cited recent evidence as motivation. The rest either cited Hegi et al. (2005) or 
nothing at all. Whereas the studies comparing multiple assays tended to be of higher qual-
ity and justified their investigations on the basis of more recent developments. Given that 
discordance between assays is essential for theoretical resolution, this activity is encourag-
ing: The studies directly testing the most pressing dimensions of uncertainty (i.e., TPCR, 
TIHC,...) also tended to better report their methods.
Figure 2.  AERO graph re-coded to show quality and uptake of evidence. Nodes are shaded 
according to Q-score. Solid edges are citations to “recent” evidence in the sample 
(within 3 years of publication). Dotted edges are citations to “old” evidence 
(more than 3 years since publication)
Finally, we should note that all three of the studies with perfect Q-scores had null results. 
This is a less encouraging sign for MGMT testing. Yet, these all compared the same two 
assays: MS-PCR and IHC. Fortunately, these are not the only assays undergoing evalua-
tion. Therefore, if we understand these three experiments as confirmatory (albeit retro-
spective) investigations, then the null result does not indicate that there is no clinically 
viable MGMT diagnostic. Instead, it indicates that MS-PCR and IHC, despite the promis-
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ing preliminary evidence, may not be the most clinically useful diagnostics. This still leaves 
open the possibility that other, more useful assays may yet be found.
6. Conclusion
The case of MGMT diagnostic testing for GBM response to TMZ provides many philo-
sophical lessons for understanding the dynamics of biomarker diagnostic translation and 
judging the quality of biomarker experiments. The most fundamental of these is that bi-
omarker translation is a more complicated process than standard, single-agent translation. 
Biomarker experiments necessarily implicate multiple theories and hypotheses, and the 
uncertainty surrounding each of these must be addressed before a biomarker can be legiti-
mately recommended for clinical use. While these theories are still in flux, it can be exceed-
ingly difficult to judge the quality of emerging evidence—even more so given that each ex-
periment may be testing a slight variation on the biomarker ensemble.
However, there is an optimistic lesson here: As the AERO model makes explicit, the 
trend of positive outcomes is consistent with a biomarker whose capacity to predict treat-
ment response is widely accepted. The reporting quality and evidence uptake revealed in 
the “Multiple” stratum of figure 2 also highlights the fact that well-coordinated work is 
now being done where it is needed most: resolution of uncertainty concerning the opti-
mal assay. Although MGMT testing is not yet recommended for general clinical use, this 
should give us reason to hope that underdetermination may soon be overcome and a clini-
cally useful assay identified.
In sum, this case illustrates that although realizing the potential of personalized medi-
cines is a high epistemic bar, it is not an insurmountable challenge. But meeting this chal-
lenge in an efficient way demands that researchers better coordinate their activities. At its 
root, the goal of personalized medicine is to furnish health-care providers with a robust un-
derstanding of the theories underlying a course of treatment: Why do only some patients 
respond to therapy? How can we prospectively test patients in order to distinguish the re-
sponders from the non-responders? Providing evidence-based answers to these questions 
requires a systematic exploration of the biomarker ensemble parameter space. This is the 
project of multiple experiments, each of which is responsible for incorporating the most re-
cent available evidence into its study design. Therefore, what makes a high-quality biomar-
ker experiment cannot solely be a function of its individual methods or rigor. It must be 
judged by its place in—and contribution to—this coordinated research effort.
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